PARP Inhibitors Study Offers Promising Results for the Treatment of Metastatic Prostate Cancer With DNA Repair Defects

A recent study published in the New England Journal of Medicine, which was the first of its kind, showed that patients with a known history of treatment-resistant prostate cancer whose tumours contained some defects involving DNA repair, could respond to a new class of drugs (i.e. PARP inhibitors). The investigators concluded that “treatment with a PARP inhibitor olaparib whose prostate cancers were no longer responding to standard therapies and who had defects in DNA repair genes led to a high response rate”.

Read the full publication by the New England Journal of Medicine here

Recent Posts